KOL Views: How much could JAK inhibitors like baricitinib shake up atopic dermatitis?

This week's success of Eli Lilly and Incyte's baricitinib – marketed for rheumatoid arthritis (RA) as Olumiant – in a pair of Phase III trials in atopic dermatitis suggests that the JAK inhibitor class may soon have a role to play in a fast-moving space where recently approved drugs like Regeneron Pharmaceuticals/Sanofi's Dupixent (dupilumab) and Pfizer's Eucrisa (crisaborole) have just begun gaining a foothold.

To provide FirstWord readers with rapid feedback on how baricitinib could fit into the treatment landscape and what to look for when detailed data are revealed, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… how excited are you about the possibility of prescribing a JAK inhibitor like baricitinib in atopic dermatitis; how concerned are you about baricitinib's safety profile and what will you key in on when detailed findings are revealed; how problematic would it be if 4 mg baricitinib, which was turned down by the FDA in RA due to cardiovascular safety issues, is the only dose that looks effective; what proportion of patients achieving an Investigator Global Assessment (IGA) score of 1 or 0 would you consider impressive; where could you see a JAK inhibitor like baricitinib fitting into the evolving treatment paradigm; and how well do you think it could compete with Dupixent in the front-line setting?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the potential of JAK inhibitors in atopic dermatitis.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.